Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!
STOCKHOLM, Sweden--(BUSINESS WIRE)--The company intends to use the capital infusion to further characterize its lead monoclonal antibody and prepare for GMP production and pre-clinical safety studies. Anki Malmborg Hager, acting CEO since February 2013, commented: “Through the capital injection we will have the opportunity to mobilize our efforts and prepare for the upcoming demanding regulatory steps we are facing in the near future. Our promising lead monoclonal antibody has shown remarkable results in in vivo disease models and we are excited to take it further in development. The strong support from Sunstone is highly welcome and I look forward to an exciting collaboration.” Claus Andersson, Partner in Sunstone Capital, states “We have followed Cantargia for the past couple of years and are intrigued to be able to be involved in its further development. The company well matches the risk/reward ratio required for our Early Engagement Program investments.”
Help employers find you! Check out all the jobs and post your resume.
